Development and validation of a prognostic nomogram for early stage non-small cell lung cancer: a study based on the SEER database and a Chinese cohort

Liang Zhou1,2†, Yahui Zhang1,3†, Wenyu Chen3†, Niu Niu2, Junjie Zhao2, Weibo Qi2* and Yufen Xu4*

Abstract

Objective: This study aimed to construct a nomogram to effectively predict the overall survival (OS) of patients with early-stage non-small-cell lung cancer (NSCLC).

Methods: For the training and internal validation cohorts, a total of 26,941 patients with stage I and II NSCLC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. A nomogram was constructed based on the risk factors affecting prognosis using a Cox proportional hazards regression model. And 505 patients were recruited from Jiaxing First Hospital for external validation. The discrimination and calibration of the nomogram were evaluated by C-index and calibration curves.

Results: A Nomogram was created after identifying independent prognostic factors using univariate and multivariate factor analysis. The C-index of this nomogram was 0.726 (95% CI, 0.718–0.735) and 0.721 (95% CI, 0.709–0.734) in the training cohort and the internal validation cohort, respectively, and 0.758 (95% CI, 0.691–0.825) in the external validation cohort, which indicates that the model has good discrimination. Calibration curves for 1-, 3-, and 5-year OS probabilities showed good agreement between predicted and actual survival. In addition, DCA analysis showed that the net benefit of the new model was significantly higher than that of the TNM staging system.

Conclusion: We developed and validated a survival prediction model for patients with non-small cell lung cancer in the early stages. This new nomogram is superior to the traditional TNM staging system and can guide clinicians to make the best clinical decisions.

Keywords: Non-small cell lung cancer, Nomogram, Overall survival, Stage I and II

Introduction

Currently, lung cancer is the leading cause of cancer-related deaths worldwide, and it is the leading cause of cancer-related deaths in China in terms of incidence and mortality from malignancies [1]. Lung cancer incidence continues to rise worldwide as a result of increased industrialization and increased access to tobacco, making lung cancer treatment a critical health issue [2]. Approximately 85% of lung cancer is non-small-cell lung cancer (NSCLC) [3]. Because the early disease is typically...
asymptomatic, up to 61% of patients have progressed to an advanced stage at the time of diagnosis, which has an inferior prognosis with a five-year survival rate of 18% [4, 5]. However, the prognosis of patients with early-stage lung cancer has a 5-year relative survival rate >80% [6]. Surgical treatment remains the current treatment of choice for patients with early-stage NSCLC. In clinical practice, the TNM staging method, which is based on the extent of the primary tumor, regional lymph node involvement, and distant metastases, is widely used to predict the prognosis of lung cancer [7]. However, at the same stage, the survival rate of patients varies substantially [8, 9]. This implies that other factors impact the prognosis of NSCLC patients. Clinical characteristics such as gender, age, histology, cell differentiation, the number of lymph nodes examined, distal metastasis, treatment modality (including surgical procedure), chemotherapy (including regimen and cycle), and radiotherapy sequence, for example, are all factors that influence individual cancer patients’ survival outcomes [10, 11].

Nomograms are currently regarded as a credible method for quantifying cancer risk and are commonly utilized in clinical studies. It is a graphical computational technique for predicting the prognosis of tumors by integrating important pathological and clinical features [12, 13]. However, nomograms predicting prognosis and guiding postoperative chemotherapy are rare in early-stage non-small cell lung cancer.

Therefore, in the present study, we built and validated the nomogram combined with several clinical variables to predict the prognosis for patients with early-stage NSCLC. In addition, this model is also validated by a unique external cohort in China. Finally, it is compared with the Norman diagram based on the traditional TNM system to evaluate its prediction effectiveness.

**Methods**

**Patients and selection criteria**

Clinicopathological data and individualized prognostic outcomes in patients with early-stage NSCLC between 2010 and 2015 were obtained from the Surveillance, Epidemiology, and End Results (SEER) database of the National Cancer Institute using SEER*Stat software (version 8.3.9; Incidence – SEER 18 Regs Custom Data (with additional treatment fields), Nov 2018 Sub (1975–2016 varying). The identification of early-stage NSCLC patients was based on the inclusion criteria as follows: (1) confirmed pathology of primary NSCLC; (2) age at diagnosis ≥18 years; (3) only patients diagnosed with pathologic stage I or pathologic stage II NSCLC were included. The exclusion criteria were as follows: (1) patients with stage III and above; (2) patients with other primary malignancies; (3) patients who lack information on survival time, metastasis and clinical staging or other incomplete information; and (4) a postoperative survival time <1 month.

In addition, to test the universality of the model, we reviewed 505 patients with pathological diagnosis of non-small cell lung cancer from January 2015 to December 2017 from Jiaxing First Hospital as an external validation cohort.

There was no requirement for ethical approval since all of the data from the SEER database was obtained in a public method. And the participants in the external validation have been ethically approved by our institution (Ethics No.LS2021-KY-140).

**Study variables**

Collect and use the following patient information: Patient characteristics (age, race, sex, vital status, survival time), tumor characteristics (Histological type, tumor size, number of tumors, laterality, primary site, grade of differentiation, AJCC stage, T stage, N stage, number of lymph nodes examined, positive lymph nodes), and Additional treatment (radiotherapy and chemotherapy) and surgical information. According to the SEER code of lung surgery, surgical procedures are classified as Sub-lobectomy, Lobectomy, Pneumonectomy, and Ablation. In the analysis some continuous variables were transformed into categorical variables, such as age, tumor size, and number of lymph nodes cleared, and patients of specific age at diagnosis were classified into four groups (<50, 50–59, 60–69, ≥70 years) according to accepted cut-off values; in this study, the three criteria of T1 (a, b, and c) were classified into (<10 mm, 10–19 mm, 20–29 mm, and ≥30 mm) for tumor size and (0, 1–9, 10–19, 20–29, and ≥30) for number of lymph nodes cleared with reference to the eighth edition of the staging system.

**Construction of the nomogram**

Using the median, continuous variables such as age and number of cleared lymph nodes were turned into categorical variables. Survival times for categorical variables were compared using the log-rank test in univariate analysis, and survival curves were drawn using the Kaplan–Meier method. The variables with P values of <0.05 were then subjected to multivariate Cox regression analysis to screen for risk factors and independent prognostic factors for OS in the training cohort, and hazard ratios (HR) and corresponding 95% confidence intervals (95% CI) for the variables were calculated. Based on these independent prognostic factors, we used the statistical software (R4.1.2, http://www.rproject.org)) to establish a nomogram to predict the probability of OS rates at 1,
3 and 5 years after radical surgery in patients with early NSCLC.

Discrimination and calibration of the nomogram
Consistency Index (C-index) and calibration curves are frequently employed to evaluate the performance and accuracy of a nomogram. The C-index values range from 0.5 to 1, and is positively correlated with the predictive performance of the model. When the value is greater than 0.7, the results demonstrated that the model has a reliable discriminant ability [14]. For the verification of the prediction model, the verification queue is utilized for internal verification, and the cases collected by our hospital are used for independent external verification, with bootstrap resampling used to create the calibration curve. The calibration curve is a straight line with a slope of 1 through the origin of the axis. The closer the predicted calibration curve is to the standard curve, the higher the predictive power of the nomogram.

DCA is a novel analytical technique that integrates all clinical consequences of a decision and then quantifies the clinical utility of a predictive model [15]. Furthermore, we employ decision curve analysis (DCA) to determine whether the nomogram is more accurate than the AJCC TNM staging system in order to further assess the benefits and advantages of the nomogram.

Results
Study cohort
Twenty-six thousand nine hundred forty-one patients with stage I and II NSCLC from 2010–2015 were extracted from the SEER database; in addition, 505 patients with stage I and II NSCLC from 2015–2017 were included as an external validation cohort from the First Hospital of Jiaxing, China. Patients in the SEER database were randomly divided into the training cohort ($n = 18,805$) and the internal validation cohort ($n = 8,136$) according to the ratio of 7:3. In the training cohort, 8300 (44.14%) males and 10505 (55.86%) females were diagnosed with a median age of 67 years, and of these patients, 12034 (63.99%) had adenocarcinoma, 14256 (75.81%) underwent lobectomy, and 3286 (17.47%) received postoperative chemotherapy. In the external validation cohort, 178 (35.25%) male patients and 327 (64.75%) female patients were diagnosed with a median age of 60 years, and of these patients, 473 (93.66%) had adenocarcinoma, 358 (70.89%) underwent sublobar resection, and 41 (8.12%) patients (8.12%) underwent postoperative chemotherapy. Table 1 shows the demographic and clinicopathological characteristics of the training and external validation groups.

Independent prognostic factors in the training cohort
Univariate analysis showed that tumor Laterality ($p < 0.005$) and tumor number ($p < 0.005$) were not independent prognostic factors, but age, sex, histological type, tumor size, tumor number, anatomical site, degree of differentiation, AJCC stage, number of examined lymph nodes, positive lymph nodes, chemotherapy and type of operation may be prognostic factors affecting OS ($P < 0.05$). Following univariate analysis, a multifactorial Cox regression analysis was performed using the Farward: LR method and the results revealed that they were all strongly associated with patient survival prognosis ($P < 0.05$). The results of the univariate and multifactorial analyses are shown in Table 2.

Prognostic nomogram for OS
According to the results of COX multivariate analysis, 11 independent risk factors, such as age, sex, histological type, tumor size, anatomical site, degree of differentiation, AJCC stage, number of lymph nodes, positive lymph nodes, Chemotherapy and type of surgery, were integrated to create the nomogram (Fig. 1). The probability of survival at 1, 3, and 5 years was easily calculated by summing the scores for each variable to compute the individual risk score and then finding the corresponding point on the survival scale.

Calibration and validation of the nomogram
C-index and AUC values were used to evaluate the accuracy and discrimination of the nomogram. In the training set, the C-index of the nomogram for OS was 0.726 (95% CI, 0.718–0.735), and the 1-, 3-, and 5-year AUCs were 0.762, 0.746, and 0.724, respectively (Fig. 2a). The C-index in the internal validation set was 0.721 (95% CI, 0.709–0.734), and the 1-, 3-, and 5-year AUCs were 0.762, 0.739, and 0.728, respectively (Fig. 2b). In the external Verification set, the C-index was 0.758 (95% CI, 0.691–0.825) and the 1-, 3- and 5-year AUCs were 0.762, 0.746, and 0.724 respectively (Fig. 2c). We used the calibration plots to check the accuracy of the nomogram and found excellent consistency between the nomogram prediction and the actual prognosis for the training set and validation set (Fig. 3). These results revealed that the nomogram exhibits excellent performance in predicting the OS of Early-Stage NSCLC patients. In addition, we compared the model performance of this nomogram with the conventional AJCC TNM staging system. In the training test, the C-index for the new nomogram and clinical staging of TNM was 0.726 (95% CI, 0.718–0.735) and 0.682 (95% CI: 0.673 to 0.691), respectively. When compared to the AJCC TNM staging method, the DCA
| Characteristics                  | Training cohort (N=18,805, n%) | Internal validation cohort (N=8136, n%) | External validation cohort (N=505, n%) |
|----------------------------------|---------------------------------|----------------------------------------|----------------------------------------|
| **Age**                          |                                 |                                        |                                        |
| <50                              | 1003 (5.33)                     | 399 (4.90)                             | 119 (23.56)                            |
| 50~59                            | 3252 (17.29)                    | 1480 (18.19)                           | 129 (25.54)                            |
| 60~69                            | 6789 (36.10)                    | 2857 (35.12)                           | 166 (32.87)                            |
| ≥70                              | 7761 (41.27)                    | 3400 (41.79)                           | 91 (18.02)                             |
| **Sex**                          |                                 |                                        |                                        |
| Female                           | 10505 (55.86)                   | 4454 (54.74)                           | 327 (64.75)                            |
| Male                             | 8300 (44.14)                    | 3682 (45.26)                           | 178 (35.25)                            |
| **Primary Site**                 |                                 |                                        |                                        |
| Upper                            | 10973 (58.35)                   | 4737 (58.22)                           | 308 (60.99)                            |
| Middle                           | 1159 (6.16)                     | 489 (6.01)                             | 44 (8.71)                              |
| Lower                            | 6172 (32.82)                    | 2710 (33.31)                           | 140 (27.72)                            |
| Other                            | 501 (2.66)                      | 200 (2.46)                             | 13 (2.57)                              |
| **Tumor Type**                   |                                 |                                        |                                        |
| Adenocarcinoma                   | 12034 (63.99)                   | 5175 (63.61)                           | 473 (93.66)                            |
| Squamous cell carcinoma          | 4482 (23.83)                    | 1957 (24.05)                           | 25 (4.95)                              |
| Adenosquamous carcinoma          | 418 (2.22)                      | 200 (2.46)                             | 1 (0.20)                               |
| Large cell carcinoma             | 374 (1.99)                      | 161 (1.98)                             | 3 (0.59)                               |
| Others                           | 1497 (7.96)                     | 643 (7.90)                             | 3 (0.59)                               |
| **Grade**                        |                                 |                                        |                                        |
| Unknown                          | 1536 (8.17)                     | 652 (8.01)                             | 4 (0.79)                               |
| Grade I                          | 3861 (20.53)                    | 1664 (20.45)                           | 307 (60.79)                            |
| Grade II                         | 7880 (41.90)                    | 3468 (42.63)                           | 97 (19.21)                             |
| Grade III                        | 5288 (28.12)                    | 2266 (27.85)                           | 60 (11.88)                             |
| Grade IV                         | 240 (1.28)                      | 86 (1.06)                              | 37 (7.33)                              |
| **Laterality**                   |                                 |                                        |                                        |
| Left                             | 7800 (41.48)                    | 3280 (40.31)                           | 213 (42.18)                            |
| Right                            | 11005 (58.52)                   | 4856 (59.69)                           | 292 (57.82)                            |
| **Stage**                        |                                 |                                        |                                        |
| IA                               | 8999 (47.85)                    | 3932 (48.33)                           | 445 (88.12)                            |
| IB                               | 5053 (26.87)                    | 2173 (26.71)                           | 42 (8.32)                              |
| IIA                              | 2524 (13.42)                    | 1119 (13.75)                           | 10 (1.98)                              |
| IIB                              | 2229 (11.85)                    | 912 (11.21)                            | 8 (1.58)                               |
| **T**                            |                                 |                                        |                                        |
| T1                               | 9696 (51.56)                    | 4234 (52.04)                           | 416 (82.38)                            |
| T2                               | 7185 (38.21)                    | 3126 (38.42)                           | 61 (12.08)                             |
| T3                               | 1924 (10.23)                    | 776 (9.54)                             | 28 (5.54)                              |
| **N**                            |                                 |                                        |                                        |
| N0                               | 16822 (89.45)                   | 7249 (89.10)                           | 490 (97.03)                            |
| N1                               | 1983 (10.55)                    | 887 (10.90)                            | 15 (2.97)                              |
| **Surgery**                      |                                 |                                        |                                        |
| Sub-lobectomy                    | 3375 (17.95)                    | 1467 (18.03)                           | 358 (70.89)                            |
| Lobectomy                        | 14256 (75.81)                   | 6151 (75.60)                           | 145 (28.71)                            |
| Pneumonectomy                    | 1110 (5.90)                     | 479 (5.89)                             | 1 (0.20)                               |
| Palliative                       | 64 (0.34)                       | 39 (0.48)                              | 1 (0.20)                               |
analysis revealed a significant increase in a net benefit for the new nomogram chart with a wide and practical range of threshold probabilities (Fig. 4).

Webserver development for the nomogram
To facilitate clinicians’ use of our Nomograms, dynamic line graphs are generated using the "DynNom" package of the R software, registering users and publishing web line graphs on shinyapps.io, the online version of the web server can be accessed directly from the following URL: https://early-stage-nsclc.shinyapps.io/DynNomapp/. After entering the predictor variables on the web server, the dynamic column line graphs can easily display the calculated survival probabilities and generate case-related figures, tables and corresponding survival graphs.

It is simple to use and does not require permission or a login password from any clinician.

Overall survival analysis
In terms of OS, the China validation cohort outperformed the SEER cohort (Kaplan–Meier curves are shown in Fig. 5). Based on the results of the multifactorial Cox regression analysis, we analyzed the survival curves of patients according to 11 variables. Based on demographic data, the results revealed that OS was considerably lower in older patients (≥70 years) than in patients of other ages, and significantly lower in male patients than in female patients. Furthermore, in terms of histologic type, adenocarcinoma has a better prognosis than squamous and large cell carcinoma, while other rare NSCLC subtypes have a really poor prognosis. On the other hand, intermediate and highly differentiated tumors, as well as early AJCC staging, had a better prognosis than poorly differentiated or undifferentiated tumors. Patients who did not undergo in situ resection had a poor prognosis, those who underwent lobectomy had the best prognosis (P<0.001), and those with larger tumors had a poor prognosis. Lymph node dissection is critical for performing the surgical treatment, and those who did not have lymph node dissection had a poor prognosis.

Discussion
Since surgical resection is still an essential treatment for early-stage NSCLC, the prognosis of postoperative survival is still dependent on the conventional AJCC staging system, which has several limitations. For example, patients with the same stage may have different prognosis, which indicates that it is also closely related to many other independent factors (such as gender,
Table 2  Selected factors in the training cohort for building the model by univariate and multivariate Cox regression analysis

| Characteristics          | Univariate analysis | P value | Multivariate analysis | P value |
|--------------------------|---------------------|---------|-----------------------|---------|
|                          | HR (95% CI)         |         | HR (95% CI)           |         |
| Age                      |                     |         |                       |         |
| <50                      | Reference           |         | Reference             |         |
| 50 ~ 59                  | 0.352(0.297 ~ 0.417) | <0.001  | 1.279(1.065 ~ 1.535)  | <0.001  |
| 60 ~ 69                  | 0.589(0.541 ~ 0.641) | <0.001  | 1.482(1.245 ~ 1.763)  | 0.008   |
| ≥ 70                     | 0.724(0.681 ~ 0.77)  | <0.001  | 1.999(1.681 ~ 2.377)  | <0.001  |
| Sex                      |                     |         |                       |         |
| Female                   | Reference           |         | Reference             |         |
| Male                     | 0.602(0.57 ~ 0.637)  | <0.001  | 1.368(1.292 ~ 1.448)  | <0.001  |
| TumorType                |                     |         |                       |         |
| Adenocarcinoma           | Reference           |         | Reference             |         |
| Squamous cell carcinoma  | 4.559(3.661 ~ 5.678) | <0.001  | 1.13(1.06 ~ 1.205)    | <0.001  |
| Adenosquamous carcinoma  | 7.951(6.371 ~ 9.924) | <0.001  | 1.227(1.051 ~ 1.432)  | <0.001  |
| Large cell carcinoma     | 8.139(6.258 ~ 10.586)| <0.001  | 1.494(1.263 ~ 1.767)  | <0.001  |
| Others                   | 9.402(7.228 ~ 12.231)| <0.001  | 0.312(0.248 ~ 0.392)  | <0.001  |
| Laterality               |                     |         |                       |         |
| Left                     | Reference           |         | Reference             |         |
| Right                    | 1.042(0.986 ~ 1.102) | 0.147   |                       |         |
| Primary site             |                     |         |                       |         |
| Upper lobe               | Reference           |         | Reference             |         |
| Middle lobe              | 0.766(0.654 ~ 0.896) | <0.001  | 1.016(0.892 ~ 1.158)  | <0.001  |
| Lower lobe               | 0.593(0.487 ~ 0.722) | <0.001  | 1.122(1.056 ~ 1.192)  | 0.807   |
| Others                   | 0.802(0.683 ~ 0.942) | <0.001  | 1.156(0.983 ~ 1.358)  | <0.001  |
| Grade                    |                     |         |                       |         |
| Unknown                  | Reference           |         | Reference             |         |
| I                        | 0.477(0.377 ~ 0.604) | <0.001  | 0.622(0.533 ~ 0.725)  | <0.001  |
| II                       | 0.269(0.215 ~ 0.336) | <0.001  | 1.142(1.001 ~ 1.303)  | <0.001  |
| III                      | 0.7(0.569 ~ 0.862)   | <0.001  | 1.488(1.304 ~ 1.698)  | <0.001  |
| IV                       | 1.106(0.898 ~ 1.361) | <0.001  | 1.261(0.982 ~ 1.618)  | <0.001  |
| Stage                    |                     |         |                       |         |
| IA                       | Reference           |         | Reference             |         |
| IB                       | 0.281(0.259 ~ 0.304) | <0.001  | 1.47(1.243 ~ 1.739)   | <0.001  |
| IIA                      | 0.539(0.498 ~ 0.584) | <0.001  | 1.977(1.641 ~ 2.382)  | <0.001  |
| IIB                      | 0.896(0.823 ~ 0.975) | <0.001  | 2.088(1.596 ~ 2.733)  | <0.001  |
| Surgery                  |                     |         |                       |         |
| Sub-lobectomy            | Reference           |         | Reference             |         |
| Lobectomy                | 0.399(0.292 ~ 0.546) | <0.001  | 0.763(0.699 ~ 0.832)  | <0.001  |
| Pneumonectomy            | 0.371(0.273 ~ 0.505) | <0.001  | 0.982(0.865 ~ 1.114)  | <0.001  |
| Palliative               | 0.716(0.52 ~ 0.984)  | <0.001  | 1.561(1.131 ~ 2.154)  | 0.775   |
| Chemotherapy             |                     |         |                       |         |
| No/unknown               | Reference           |         | Reference             |         |
| Yes                      | 0.568(0.534 ~ 0.605) | <0.001  | 0.858(0.795 ~ 0.925)  | <0.001  |
| Nodes                    |                     |         |                       |         |
| 0                        | Reference           |         | Reference             |         |
| 1 ~ 9                    | 1.092(0.919 ~ 1.297) | <0.001  | 0.628(0.566 ~ 0.698)  | <0.001  |
| 10 ~ 19                  | 0.817(0.698 ~ 0.956) | <0.001  | 0.533(0.475 ~ 0.599)  | <0.001  |
| 20 ~ 29                  | 0.793(0.675 ~ 0.931) | <0.001  | 0.449(0.387 ~ 0.521)  | <0.001  |
| ≥ 30                     | 0.772(0.641 ~ 0.93)  | <0.001  | 0.542(0.451 ~ 0.652)  | <0.001  |
age, tumor histology, degree of tumor differentiation, etc.), not only the tumor size and lymph node involvement in the TNM staging system, so this staging system does not provide clinicians with individualized and more accurate prognosis prediction. Therefore there is a need to establish a well-developed prognostic model to compensate for this limitation. In recent years, many researchers have attempted to build similar survival prediction models, for example, Zuo [16] built a prediction model from the SEER database for patients with stage Ib NSCLC and performed external validation, but the C-index obtained for the training and external validation cohorts was 0.637 (95% CI 0.634–0.641) and 0.667 (95% CI 0.656–0.678). CI 0.656–0.678). The prediction model developed by Zhang with 443 patients with early-stage NSCLC had a C-index of 0.622 (95% CI: 0.572–0.672), although higher than the conventional TNM staging system with a C-index of 0.596 (95% CI: 0.551–0.641), but lacked external validation [17]. The accuracy achieved by the current prediction models developed regarding

| Characteristics | Univariate analysis | P value | Multivariate analysis | P value |
|-----------------|--------------------|---------|----------------------|---------|
|                 | HR (95% CI)        |         | HR (95% CI)          |         |
| Positive        |                    |         |                      |         |
| No/unknown      | Reference          | <0.001  | Reference            | <0.001  |
| Yes             | 0.457(0.426 ~ 0.491) | <0.001  | 1.339(1.165 ~ 1.539) | <0.001  |
| TumorSize       |                    |         |                      |         |
| ≤ 9 mm          | Reference          | <0.001  | Reference            | <0.001  |
| 10–19 mm        | 0.262(0.217 ~ 0.317) | <0.001  | 1.289(1.058 ~ 1.572) | <0.001  |
| 20–29 mm        | 0.392(0.364 ~ 0.421) | <0.001  | 1.662(1.363 ~ 2.027) | 0.012   |
| ≥ 30 mm         | 0.570(0.533 ~ 0.61)  | <0.001  | 2.207(1.797 ~ 2.712) | <0.001  |
| Number          |                    |         |                      |         |
| 1               | Reference          |         |                      |         |
| ≥ 2             | 0.93(0.864 ~ 1.001)  | 0.052   |                      |         |

**Table 2** (continued)

![Fig. 1 Prognostic nomograms of 1-, 3-, and 5-year OS](image-url)
patients with early-stage NSCLC is not particularly high and therefore difficult to apply in clinical practice. In contrast, this study not only modeled based on a large sample size, but also validated with a large amount of external data, and achieved a high accuracy. In addition, compared to previous models our study attempted to incorporate more parameters to develop a more reliable postoperative predictive nomogram for patients with early-stage NSCLC.

Through univariate and multivariate analyses, we discovered that age, sex, histological type, tumor size, tumor number, anatomical site, degree of differentiation, AJCC stage, number of examined lymph nodes, positive lymph nodes, chemotherapy, and type of surgery were independent factors affecting OS in this large population study, which is consistent with the findings of similar related studies [12, 18]. According to our nomogram, tumor pathological type was the strongest predictor of OS, with large cell lung cancer having the poorest prognosis and adenocarcinoma being the best pathological type. Secondly, tumors with surgical sites occurring in the upper lobes have a relatively good prognosis, and the findings of Li [19] and Lee [20] are consistent with this, suggesting that it may be related to differences in anatomical site, ease of surgical site, degree of lymph node clearance, and adjacent surrounding tissues. It is worth noting that although the anatomy of the left and right sides of the lung differed, the affected side of the tumor ($P = 0.147$) was not a significant independent influencing factor.

The degree of tumor differentiation is closely related to the biological behavior of different types of tumors and therefore naturally affects the prognosis of patients [18]. The findings suggest that the degree of tumor differentiation is positively correlated with the malignancy and aggressiveness of the tumor [21]. However, some scholars disagree that hypodifferentiation is not associated with poorer prognosis in early-stage NSCLC [22]. In our study, poor differentiation was significantly associated with poor survival in early-stage NSCLC, suggesting that this factor may provide useful information for defining the aggressiveness of the tumor. Although the degree of differentiation is now included in the pathological staging of early esophageal cancer [23], it is not included in the TNM staging criteria of lung
cancer. Considering that the degree of differentiation can guide surgery and predict survival, we strongly recommend that the degree of differentiation be included in the forthcoming TNM classification criteria.

In early-stage NSCLC, tumor size is an important independent predictor of prognosis. Our findings support the widespread perception that the smaller the tumor, the better the prognosis. The eighth edition of TNM staging of lung cancer divides T1 into three subgroups of a, b, and c on a per centimeter basis, further indicating that tumor size is an extremely important prognostic factor [24]. Our study divided the variables of tumor size according to T1 criteria, which better reflected the survival differences of different tumor sizes compared with previous models. In the training cohort, lobectomy had a better OS, but in the external validation population, where sublobar resection cases were predominant, postoperative survival was not worse than lobectomy. This deserves additional investigation, particularly for patients with stage I NSCLC ≤2 cm, where there is no consensus on the best surgical approach. A series of prospective studies on this issue have been conducted in North America (CALGB140503) [25] and Japan (JCOG0802/WJOG4607L) [26], and the latest published results suggest that subpneumonectomy is non-inferior or even slightly superior to lobectomy in early-stage NSCLC [27–31]. Presently, an increasing number of surgical teams are endorsing this outcome and preferring sublobar resection.

The number of lymph nodes removed is an important prognostic factor in various cancers [32, 33], and the thoroughness of lymph node clearance will determine the likelihood of resection of metastatic lymph nodes and lead to accurate staging, which will guide the adjuvant treatment of patients [34]. Similar studies have shown that the higher the number of lymph nodes examined, the better the prognosis [18]. The ACOSOG Z0030 trial, on the other hand, indicated that systemic lymph node dissection no longer improves the oncologic prognosis of early-stage NSCLC if thorough lymph node sampling reveals negative lymph nodes [35]. A study by Wo [36] in patients with stage IA NSCLC showed a decreased survival benefit when more than 10 lymph nodes were examined. In this study, which also included stage II patients, the survival benefit was reduced when the number of lymph nodes cleared exceeded 30. This difference leads us to believe that lymph node dissection should

Fig. 3 Calibration curves predicting the 1-, 3-, and 5-year OS of patients in the training cohort (a) the internal validation cohort (b) and the external validation cohort (c). The x-axis indicates the predicted survival probability, and the y axis indicates the actual survival probability. The 45-degree line (gray line) indicates that the prediction agrees with actuality.
be further investigated depending on the stage, or that the number of stations should be utilized instead of the number.

To minimize overfitting, we verified and calibrated the model, which exhibited reasonably constant discriminative power and calibration curves demonstrating good agreement between predicted survival probabilities and actual data, indicating that the established model is repeatable and reliable. Moreover, the nomogram model has good applicability in the external validation cohort. Besides, the C-index of this nomogram (0.726 (95% CI, 0.718–0.735)) was higher than that of the conventional TNM staging system (0.682 (95% CI: 0.673–0.691)), and the DCA curve results demonstrated that the model had greater discriminatory power and clinical utility than the TNM staging system.

However, there are still some limitations of the present study. First, this was a retrospective and non-randomized study subject to all the limitations inherent in the study design. Therefore, prospective studies are also needed to test the validity of this model. Second, there are some limitations to using the SEER database, which only provides crude mortality data and lacks some important covariates, such as smoking history, vascular invasion, lymphovascular invasion, neural invasion, the presence of cancer thrombi, an up-to-date classification of pathological types, genetic mutations, and time to disease progression, as well as specific chemotherapy and targeted therapy, all of which are important prognostic factors in NSCLC [37, 38]. Finally, our Norman plot was created using a large population and validated using external data with good discrimination and consistency, but the external validation data is only for cases in a single region and is not representative of other regions. Hence, more data from different regions is required for external validation. As a result, more multicenter studies and prospective data collection incorporating other potential variables are required to improve this nomogram.
Conclusions
We have developed and validated a nomogram based on the SEER large population database to provide a convenient and reliable individualized postoperative survival prediction tool for patients with early-stage non-small cell lung cancer.

This new nomogram outperforms the conventional TNM staging system in predicting 1-, 3-, and 5-year survival rates for patients with early-onset non-small cell lung cancer, assisting clinicians in predicting patient prognosis and making treatment decisions. More prospective studies are needed in the future to continuously refine studies related to the survival prognosis of patients with early-stage non-small cell lung cancer.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12885-022-10067-8.

Additional file 1. External verification.
Additional file 2. Internal validation.
Additional file 3. Training queue.
Acknowledgements

The authors thank all patients and institutions involved in this study, especially the ability to have open access to the SEER database.

Guidelines and regulations

This study was conducted in concordance with the Helsinki Declaration.

Authors’ contributions

Conception and design: Liang Zhou, Yufan Xu, Weibo Qi, Wenyu Chen. Collection and assembly of data: Liang Zhou, Yahui Zhang, Niu Niu, Xinjie Ma. Data analysis and interpretation: All authors. Manuscript preparation: All authors. Manuscript proofing: All authors. Final approval of the manuscript: All authors.

Funding

This research was funded by Natural Science Foundation of Zhejiang province (NO. LQ20H160057); the Key Discipline of Jiaxing Medicine Construction Project (grant No.2019-zc-04, 2019-zc-09, 2019-zc-11); the Jiaxing Key Laboratory of Precision Treatment for Lung Cancer, Scientific Technology Plan Program for Healthcare in Zhejiang Province (NO. 2021RC031, 2022KY377); Science and technology project of Jiaxing[2019AY32030, 2020AY30012, 2021AY30024].

Availability of data and materials

The datasets generated and/or analysed during the current study are available in the SEER database (http://seercancer.gov) repository. All data generated or analyzed during this study are included in this published article and its supplementary information files.

Declarations

Ethics approval and consent to participate

This study was approved by the Ethics Committee of Jiaxing First Hospital (zhejiang, China) (Ethics No. LS2021-KY-140). All patients or next-of-kin in the external validation cohort provided written informed consent for the case details to be published. We were permitted to have Internet access to the SEER database (http://seercancer.gov) by the SEER administration. This study details to be published. We were permitted to have Internet access to the SEER database.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

1Bengbu Medical College Graduate Department, Bengbu 233000, China. 2Department of Cardio-Thoracic Surgery, Affiliated Hospital of Jiaxing University, 314000 Zhejiang, People’s Republic of China. 3Department of Respiratory, Affiliated Hospital of Jiaxing University, 314000 Zhejiang, People’s Republic of China. 4Department of Medical Oncology, Affiliated Hospital of Jiaxing University, 314000 Zhejiang, People’s Republic of China.

Received: 29 April 2022 Accepted: 5 September 2022

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
2. Wu W, Wang L, Zhou C. Lung cancer in China: current and prospects. Curr Opin Oncol. 2021;33(3):1140–6.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
4. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(9):363–85.
5. Noone A, Howlader N, Krapcho M. SEER Cancer Statistics Review, 1975–2015; Based on November 2017 SEER data submission, posted to the SEER website April 2018. Bethesda: National Cancer Institute; 2018. p. 2019.
6. Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth Edition Lung Cancer Stage Classification. Chest. 2017;151(1):193–203.
7. Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings: in the forthcoming (Eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11(1):39–51.
8. Chansky K, Sculler JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. Thorac Oncol. 2009;4(7):792–801.
9. Kawaguchi T, Takada M, Kudo A, Matsumura A, Fukai S, Tamura A, Saito R, Maruyama Y, Kawaihara M, Ignatius Ou SH. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol. 2010;5(5):620–30.
10. Pan H, Shi X, Xiao D, He L, Zhang Y, Liang W, Zhao Z, Guo Z, Zou X, Zhang J, et al. Nomogram prediction for the survival of the patients with small cell lung cancer. J Thorac Dis. 2017;9(3):507–18.
11. Wang S, Yang L, Ci B, Maclean M, Gerber DE, Xiao G, Xie Y. Development and Validation of a Nomogram Prognostic Model for SCLC Patients. J Thorac Oncol. 2018;13(9):1338–48.
12. Liang W, Zhang L, Jiang G, Wang Q, Liu L, Liu D, Wang Z, Zhu Z, Deng Q, Xiong X, et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J Clin Oncol. 2015;33(8):861–9.
13. Zheng XQ, Huang JF, Lin JL, Chen L, Zhou TT, Chen D, Lin DD, Shen JF, Wu AM. Incidence, prognostic factors, and a nomogram of Lung cancer with bone metastasis at initial diagnosis: a population-based study. Transl Lung Cancer Res. 2019;8(4):367–79.
14. Wei RL, Zhang LW, Li JG, Yang FD, Yue YK, Wei XT. Behavior-Oriented Nomogram for the Stratification of Lower-Grade Gliomas to Improve Individualized Treatment. Front Oncol. 2020;10:538133.
15. Vickers AJ, Elinck EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making. 2006;26(6):565–74.
16. Zuo Z, Zhang G, Song P, Yang J, Li S, Zhou X, Tan Q, Wang L, Xue Q, Gao S, et al. Survival nomogram for stage II non-small-cell lung cancer patients, based on the SEER database and an external validation cohort. Ann Surg Oncol. 2021;28(7):3941–50.
17. Zhang J, Fan J, Yin R, Geng L, Zhu M, Shen W, Wang Y, Cheng Y, Li Z, Dai J, et al. A nomogram to predict overall survival of patients with early stage non-small cell lung cancer. J Thorac Dis. 2019;11(12):S407–16.
18. Zeng Y, Mayne N, Yang C, D’Amico TA, Ng CSH, Liu CC, Petersen RH, Rocco G, Brunelli A, Liu J, et al. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. Ann Surg Oncol. 2019;26(7):2053–62.
19. Li C, Liu J, Lin J, Li Z, Shang X, Wang H. Poor survival of non-small-cell lung cancer patients with main bronchus tumor: a large population-based study. Future Oncol. 2019;15(24):2819–27.
20. Lee HW, Lee CH, Park YS. Location of stage I-III non-small cell lung cancer and survival rate: systematic review and meta-analysis. Thorac Cancer. 2018;9(2):1614–22.
21. Paselio G, Zago G, Lunardi F, Urso L, Kern I, Vlaci G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29(5):1258–65.
22. Agnarson M, Brahmanday G, Chmielewski GW, Welsh RJ, Ravikrishnan KP. Age, tumor size, type of surgery, and gender predict survival in early stage (stage I and II) non-small cell lung cancer after surgical resection. Lung Cancer. 2010;68(3):398–402.
23. Zeng Y, Mayne N, Yang C, D’Amico TA, Ng CSH, Liu CC, Petersen RH, Rocco G, Brunelli A, Liu J, et al. A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. Ann Surg Oncol. 2019;26(7):2053–62.
24. Paselio G, Zago G, Lunardi F, Urso L, Kern I, Vlaci G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, et al. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time. Ann Oncol. 2018;29(5):1258–65.
26. Nakamura K, Saji H, Nakajima R, Okada M, Asamura H, Shibata T, Nakamura S, Tada H, Tsuboi M. A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L). Jpn J Clin Oncol. 2010;40(3):271–4.

27. Takamoto S, Ozumi H, Suzuki J, Suzuki K, Kabasawa T. Video-Assisted Thoroscopic Segmentectomy for Deep and Peripheral Small Lung Cancer. Thorac Cardiovasc Surg. 2022;70(3):233–38.

28. Darras M, Ojanguren A, Forster C, Zellweger M, Perentes JY, Krueger T, Gonzalez M. Short-term local control after VATS segmentectomy and lobectomy for solid NSCLC of less than 2 cm. Thorac Cancer. 2021;12(4):453–61.

29. Mimae T, Okada M. Are segmentectomy and lobectomy comparable in terms of curative intent for early stage non-small cell lung cancer? Gen Thorac Cardiovasc Surg. 2020;68(7):703–6.

30. Handa Y, Tsutani Y, Mimae T, Miyata Y, Okada M. Complex segmentectomy in the treatment of stage IA non-small-cell lung cancer. Eur J Cardiothorac Surg. 2020;57(1):114–21.

31. Lutz JA, Seguin-Gwelet A, Gregoriou M, Brian E, Girard P, Gosset D. Oncological results of full thoracoscopic major pulmonary resections for clinical Stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2019;55(2):263–70.

32. Hua J, Zhang B, Xu J, Liu J, Ni Q, He J, Zheng L, Yu X, Shi S. Determining the optimal number of examined lymph nodes for accurate staging of pancreatic cancer: An analysis using the nodal staging score model. Eur J Surg Oncol. 2019;45(6):1069–76.

33. Wang Y, Zhang J, Guo S, Dong Z, Meng X, Zheng G, Yang D, Zheng Z, Zhao Y. Implication of lymph node staging in migration and different treatment strategies for stage T2N0M0 and T1N1M0 resected gastric cancer: a SEER population analysis. Clin Transl Oncol. 2019;21(11):1499–509.

34. Osarogiagbon RJ, Ogbona O, Yu X. Number of lymph nodes associated with maximal reduction of long-term mortality risk in pathologic node-negative non-small cell lung cancer. Ann Thorac Surg. 2014;97(2):385–93.

35. Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Iculea RI, Jones DR, Mckenna RJ, Landrenau RJ, Rusch WV. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non–small cell carcinoma: Results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg. 2011;141(3):662–70.

36. Wo Y, Yang H, Zhang Y, Wo J. Development and External Validation of a Nomogram for Predicting Survival in Patients With Stage IA Non-small Cell Lung Cancer ≤2 cm Undergoing Sublobectomy. Front Oncol. 2019;9:1385.

37. Kent MS, Mandrekar SJ, Landrenau R, Nichols F, Foster NR, DiPietrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, et al. A nomogram to predict recurrence and survival of high-risk patients Undergoing Sublobar Resection For Lung Cancer: an analysis of a multicenter prospective study (ACOSOG Z4032). Ann Thorac Surg. 2016;102(1):239–46.

38. Matsumura Y, Hishida T, Shimada Y, Ishii G, Aokage K, Yoshida J, Nagai K. Impact of extratumoral lymphatic permeation on postoperative survival of non-small-cell lung cancer patients. J Thorac Oncol. 2014;9(3):337–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.